Skip to main content

Table 2 Univariate and multivariate analysis of risk factors in the endometrioma and/or endometriosis-related pain recurrence and nonrecurrence groups

From: Risk factors for postoperative recurrence of ovarian endometriosis: long-term follow-up of 358 women

Factor Univariate analysis Multivariate analysis
Relative risk 95%CI P value Relative risk 95%CI P value
Age at surgery (per 5 years) 0.764 0.615–0.949 0.015 0.738 0.520–1.048 0.090
Gravida
 0 1.000      
 1 0.673 0.370–1.224 0.194    
 2 (and above) 0.757 0.557–1.029 0.075    
Parity
 0 1.000      
 1 0.478 0.261–0.876 0.017 0.002 0.000–1.222 0.974
 2 0.216 0.011–4.254 0.314    
BMI 0.820 0.478–1.407 0.470    
Infertility 1.527 0.882–2.644 0.131    
Extent of dysmenorrhea     1.711 1.175–2.493 0.005
 None 1.000      
 Mild 4.506 1.413–14.368 0.011    
 Moderate 2.451 1.433–4.193 0.001    
 Severe 1.771 1.254–2.502 0.001    
Duration of dysmenorrhea (per year) 1.120 1.054–1.190 < 0.001 1.026 0.944–1.114 0.548
Extent of dysmenorrhea 2.534 1.408–4.563 0.002    
VAS (0-4)
VAS (5-10)
Dyspareunia 1.734 1.049–2.866 0.032 1.081 0.511–2.285 0.839
Chronic pelvic pain 0.959 0.503–1.828 0.898    
Dyschezia 0.735 0.268–2.018 0.550    
Presence of leiomyoma 1.661 0.969–2.848 0.065 1.713 0.825–3.555 0.149
Presence of adenomyosis 1.629 1.008–2.630 0.046 1.446 0.719–2.908 0.301
Presence of deep infiltrating endometriosis 1.380 0.849–2.243 0.194 1.118 0.582–2.149 0.737
CA125 level (45 U/ml) 1.856 1.072–3.214 0.021 1.020 0.965–1.078 0.491
rARSM stage 1.204 0.774–1.873 0.409    
Bilateral involvement 1.046 0.650–1.684 0.853    
Large dimeter (per 10 mm) 1.016 0.944–1.093 0.674    
Postoperative medication
 None 1.000      
 GnRHa 21.818 0.125–3810.382 0.242    
 OCP 4.057 0.019–856.392 0.610    
 Mirena 2.741 0.048–155.496 0.624    
 GnRHa+Mirena 1.991 0.375–9.730 0.436    
Postoperative pregnancy 0.938 0.655–1.344 0.728 0.649 0.460–0.914 0.013
  1. Abbreviations: BMI Body mass index, CA-125 Cancer antigen 125, GnRHa Gonadotropin-releasing hormone agonist, OCP Oral contraceptive pills, VAS Visual analogue score